GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Accounts Payable

CG Oncology (CG Oncology) Accounts Payable : $4.66 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Accounts Payable?

CG Oncology's Accounts Payable for the quarter that ended in Mar. 2024 was $4.66 Mil.

CG Oncology's quarterly Accounts Payable increased from Sep. 2023 ($1.96 Mil) to Dec. 2023 ($3.24 Mil) and increased from Dec. 2023 ($3.24 Mil) to Mar. 2024 ($4.66 Mil).

CG Oncology's annual Accounts Payable declined from Dec. 2021 ($1.00 Mil) to Dec. 2022 ($0.99 Mil) but then increased from Dec. 2022 ($0.99 Mil) to Dec. 2023 ($3.24 Mil).

CG Oncology Accounts Payable Historical Data

The historical data trend for CG Oncology's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Accounts Payable Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Accounts Payable
1.00 0.99 3.24

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Accounts Payable Get a 7-Day Free Trial 0.99 - 1.96 3.24 4.66

CG Oncology Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

CG Oncology Accounts Payable Related Terms

Thank you for viewing the detailed overview of CG Oncology's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Accounts Payable
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024